OSE Immunotherapeutics Employee Directory
Biotechnology ResearchPays de la Loire, France51-200 Employees
OSE Immunotherapeutics is a French biotechnology research company based in Nantes that focuses on developing first-in-class assets in immuno-oncology and immuno-inflammation, with a workforce of 51-200 employees. Its product portfolio includes Tedopi, a therapeutic cancer vaccine in Phase 3 for second-line NSCLC in HLA-A2+ patients with secondary resistance, as well as Lusvertikimab (an IL-7R antagonist) with a positive Phase 2 in ulcerative colitis and preclinical work in ALL, and OSE-279 (anti-PD1) with early Phase 1/2 results. The pipeline also features FR-104/VEL-101 (anti-CD28 mAb) developed in partnership with Veloxis for transplantation, an anti-SIRPα mAb developed with Boehringer Ingelheim, and ABBV-230 (ChemR23 agonist mAb) developed with AbbVie. OSE Immunotherapeutics operates four proprietary drug discovery platforms: Pro-resolutive mAb platform, Myeloid Checkpoint platform, BiCKI, and an mRNA Therapeutic platform. Strategic collaborations include an exclusive Veloxis licensing and co-development agreement established in 2021, along with partnerships with Boehringer Ingelheim and AbbVie; in 2026 the company announced leadership changes with Marc Le Bozec appointed as CEO and Thomas Gidoin named Deputy CEO, and scheduled governance events such as an AGM in Paris.
1-888-653-2347 
support@leadiq.com 
